Compare Noble Corporation plc (NE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Organon & Co. Common Stock — how do they compare? Noble Corporation plc trades at $42.9 (market cap $6.93B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Noble Corporation plc is the larger of the two by market cap, and Noble Corporation plc pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 27 Days and Organon & Co. Common Stock for 0 Days on average.
| NE | OGN | |
|---|---|---|
Market Cap | $6.93B | $3.62B |
Volume | 747,410 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $54.37 | $13.81 |
52-Week Low | $27.45 | $5.70 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $8.36B | $11.04B |
Dividend Yield | 4.61% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $43.42, up 1.12% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income falling to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though investor sentiment is tempered by an ongoing legal investigation and inconsistent quarterly earnings performance.
Outlook remains cautious with analyst consensus price target of $52 offering 20% upside potential, but risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. The stock presents moderate opportunity for value investors given reasonable valuation multiples, but requires careful monitoring of contract execution and resolution of legal matters.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
